Champions Oncology (CSBR) director granted 13,790 options at $6.80
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to purchase Common Stock | 13,790 | $6.80 | $94K |
Footnotes (1)
- F1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CSBR disclose in this Form 4?
What is the exercise price of the reported options for CSBR?
When were the options granted and when do they expire for CSBR?
What is the vesting schedule for the CSBR director options?
How is ownership reported for these CSBR options?
Who is the issuer in this Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.